Our cell microarray tech is the leading solution for discovering human primary receptors & off-targets for antibodies, proteins, small molecules, viruses & more
Retrogenix’s Asia Pacific Business Development Manager Dr Mark Aspinall-O’Dea will be attending and presenting at the 9th Biologics World Taiwan from 8th – 9th September. For more information please visit : https://t.co/U44u9jR6y1
We are proud to be part of an organisation that values the importance of inspiring the next generation of scientists. At Charles River, a summer science fair has been organised for the children of CRL team members. The theme is: 'Together, We Create Healthier Lives!'. #LIFEatCRL
We are able to screen a large selection of biotherapeutics, whole cells and small molecules against our comprehensive protein library. To find out which type of study best suits your needs, please get in touch.
We are looking forward to a busy events calendar this year, as hopefully the world begins to return to some form of normality.
Below are some of the key conferences we will be attending in the second half of 2021:
A new case study "Use of Retrogenix cell microarray technology to confirm specificity of diagnostic molecules created using the NanoMab Platform" is now available to view online.
To view the full study please visit :
https://t.co/u4gNukpWbm
We are delighted to share our recent Cell Therapy Webinar, Assessing off-target liabilities and generating tox data for INDs. To watch the full webinar or for more information please visit : https://t.co/EvxM9wXnos
As June marks #pridemonth 2021
Here at Retrogenix | A Charles River company we ensure we have a diverse and inclusive work environment made up of employees from various cultures, backgrounds and communities. Our employees can come to work without fear of discrimination.
#Pride
Longtime Charles River Exec Birgit Girshick recently took part in a Q&A with Endpoint News discussing how Covid-19 has changed the game amid an M&A flurry at Charles River. To read the full article click here: https://t.co/ci9QuSDBlS
We are delighted to share a new paper which has been published by the CIDR, Seattle. The paper shows how Platelet Derived Growth Factor Receptor β (PDGFRβ) is a Host Receptor for the human malaria parasite adhesin TRAP. To see the full paper click here : https://t.co/0ZuTRD3D7Q
We are looking forward to a busy events calendar this year, as hopefully the world begins to return to some form of normality.
Below are some of the key conferences we will be attending in the second half of 2021:
Data presented at ASGCT shows how development of a functional off-target screen within the cell microarray platform may negate the need for separate follow up studies after specificity assessment. View and download the poster here:
https://t.co/5rMNoAB0GZ
Join us at the Antibody Industrial Symposium from 22nd-25th June. Our European Business Development Manager Diogo Rodrigues Ferreirinha will be presenting at the conference.
For more information please visit: https://t.co/DVoolSqte1
We're delighted to share with you a new case study, in which a pre-IND off-target screen was conducted on a human monoclonal antibody (mAb) provided by @SimcerePharm : https://t.co/slyCwMMtEQ
We will be attending Bio Digital US 2021 from 14th - 18th June. Our North American Business Development Manager Brad Gartland will be available so please contact him directly if you would like a discussion.
For more information please visit https://t.co/9VfswXMwEK
We are delighted to be attending the 2021 BioKorea International Convention from 9-11th June.
For more information please visit https://t.co/altroKbK7h or to register https://t.co/mRipJq1t6f
We are delighted to be attending and presenting at the Antibody Engineering and Therapeutics Conference from 8th - 10th June.
Diogo Rodrigues Ferreirinha, Retrogenix’s European Business Development Manager will be presenting on day two of the meeting.
https://t.co/xPBPlCPtG1